靶向治疗时代超越手术观点：脊柱转移瘤治疗前脊柱外科医生应了解的内容。
The Targeted Therapies Era Beyond the Surgical Point of View: What Spine Surgeons Should Know Before Approaching Spinal Metastases.
机构信息
Dipartimento di Neuroscienze, Neurosurgery, Universita degli Studi di Torino, Torino, Italy.
Dipartimento di Scienze Mediche, Pathology, Universita degli Studi di Torino, Torino, Italy.
出版信息
Cancer Control. 2019 Jan-Dec;26(1):1073274819870549. doi: 10.1177/1073274819870549.
Abstract
In the last few years, the treatment of spinal metastases has significantly changed. This is due to the advancements in surgical technique, radiotherapy, and chemotherapy which have enriched the multidisciplinary management. Above all, the field of molecular biology of tumors is in continuous and prosperous evolution. In this review, the molecular markers and new approaches that have radically modified the chemotherapeutic strategy of the most common metastatic neoplasms will be examined together with clinical and surgical implications. The experience and skills of several different medical professionals are mandatory: an interdisciplinary oncology team represents the winning strategy in the treatment of patients with spinal metastases.
摘要
在过去的几年中，脊柱转移瘤的治疗发生了显著变化。这是由于手术技术、放疗和化疗的进步丰富了多学科管理。最重要的是，肿瘤分子生物学领域正在不断蓬勃发展。在这篇综述中，我们将探讨共同改变最常见转移性肿瘤的化疗策略的分子标志物和新方法，并探讨其临床和手术意义。需要有多位不同医学专业人员的经验和技能：肿瘤多学科团队是治疗脊柱转移瘤患者的制胜策略。
相似文献
1
The Targeted Therapies Era Beyond the Surgical Point of View: What Spine Surgeons Should Know Before Approaching Spinal Metastases.靶向治疗时代超越手术观点：脊柱转移瘤治疗前脊柱外科医生应了解的内容。
Cancer Control. 2019 Jan-Dec;26(1):1073274819870549. doi: 10.1177/1073274819870549.
2
New therapeutics in spine metastases.脊柱转移瘤的新疗法
Expert Rev Neurother. 2005 Nov;5(6):831-40. doi: 10.1586/14737175.5.6.831.
3
Surgical results of metastatic spinal cord compression (MSCC) from non-small cell lung cancer (NSCLC): analysis of functional outcome, survival time, and complication.非小细胞肺癌（NSCLC）所致转移性脊髓压迫（MSCC）的手术结果：功能结局、生存时间及并发症分析
Spine J. 2016 Mar;16(3):322-8. doi: 10.1016/j.spinee.2015.11.005. Epub 2015 Nov 14.
4
The Effect of Introducing the Spinal Instability Neoplastic Score in Routine Clinical Practice for Patients With Spinal Metastases.在脊柱转移瘤患者的常规临床实践中引入脊柱不稳定肿瘤评分的效果。
Oncologist. 2016 Jan;21(1):95-101. doi: 10.1634/theoncologist.2015-0266. Epub 2015 Dec 14.
5
[Role of surgery in the management of vertebral metastases. General revue].[手术在脊柱转移瘤治疗中的作用。综述]
Cancer Radiother. 2016 Oct;20(6-7):484-92. doi: 10.1016/j.canrad.2016.07.086. Epub 2016 Sep 7.
6
Surgical strategy for spinal metastases.脊柱转移瘤的手术策略
Spine (Phila Pa 1976). 2001 Feb 1;26(3):298-306. doi: 10.1097/00007632-200102010-00016.
7
Treatment of spine metastases in cancer: a review.癌症脊柱转移的治疗：综述。
J Int Med Res. 2020 Apr;48(4):300060519888107. doi: 10.1177/0300060519888107. Epub 2019 Dec 26.
8
Surgical Treatment in Patients with Spinal Tumors - Differences in Surgical Strategies and Malignancy-Associated Problems. An Analysis of 474 Patients.脊柱肿瘤患者的外科治疗——手术策略及恶性肿瘤相关问题的差异。对474例患者的分析
Ortop Traumatol Rehabil. 2015 May-Jun;17(3):229-40. doi: 10.5604/15093492.1162422.
9
Current paradigms for metastatic spinal disease: an evidence-based review.转移性脊柱疾病的当前范式：一项基于证据的综述。
Ann Surg Oncol. 2014 Jan;21(1):248-62. doi: 10.1245/s10434-013-3324-8. Epub 2013 Oct 22.
10
Evolution in treatment strategy for metastatic spine disease: Presently evolving modalities.转移性脊柱疾病治疗策略的演变：当前不断发展的方式。
Eur J Surg Oncol. 2017 Sep;43(9):1784-1801. doi: 10.1016/j.ejso.2017.05.006. Epub 2017 May 17.
引用本文的文献
1
Overview of Molecular Prognostication for Common Solid Tumor Histologies - What the Surgeon Should Know.常见实体瘤组织学类型的分子预后评估概述——外科医生应了解的内容。
Global Spine J. 2025 Jan;15(1_suppl):6S-15S. doi: 10.1177/21925682241250327.
2
A Multidisciplinary Update on Treatment Modalities for Metastatic Spinal Tumors with a Surgical Emphasis: A Literature Review and Evaluation of the Role of Artificial Intelligence.以手术为重点的转移性脊柱肿瘤治疗方式的多学科最新进展：文献综述与人工智能作用评估
Cancers (Basel). 2024 Aug 8;16(16):2800. doi: 10.3390/cancers16162800.
3
Carbon Fiber-Reinforced Polyetheretherketone Spinal Implants for Treatment of Spinal Tumors: Perceived Advantages and Limitations.用于治疗脊柱肿瘤的碳纤维增强聚醚醚酮脊柱植入物：感知到的优势与局限性
Neurospine. 2023 Mar;20(1):317-326. doi: 10.14245/ns.2244920.460. Epub 2023 Mar 31.
4
Spinal Metastases and the Evolving Role of Molecular Targeted Therapy, Chemotherapy, and Immunotherapy.脊柱转移瘤以及分子靶向治疗、化疗和免疫治疗的不断演变的作用
Neurospine. 2022 Dec;19(4):978-993. doi: 10.14245/ns.2244290.145. Epub 2022 Dec 31.
5
Long-Term Clinical Outcomes of Patients with Colorectal Cancer with Metastatic Epidural Spinal Cord Compression Treated with Hybrid Therapy (Surgery Followed by Stereotactic Body Radiation Therapy).混合治疗（手术后继以立体定向体部放射治疗）治疗转移性硬膜外脊髓压迫的结直肠癌患者的长期临床结局。
World Neurosurg. 2023 Jan;169:e89-e95. doi: 10.1016/j.wneu.2022.10.053. Epub 2022 Oct 19.
6
Prolonged durability of extensive contiguous spinal metastasis stabilization in non-small cell lung cancer patients receiving targeted therapy: two case reports and a literature review.接受靶向治疗的非小细胞肺癌患者广泛连续脊柱转移稳定的长期耐久性：两例病例报告和文献复习。
J Int Med Res. 2022 Jun;50(6):3000605221105003. doi: 10.1177/03000605221105003.
7
Attitudes and trends in the use of radiolucent spinal implants: A survey of the North American Spine Society section of spinal oncology.可透射线脊柱植入物的使用态度和趋势：北美脊柱学会脊柱肿瘤学分会的一项调查
N Am Spine Soc J. 2022 Feb 23;10:100105. doi: 10.1016/j.xnsj.2022.100105. eCollection 2022 Jun.
8
Craniovertebral junction chordomas: Case series and strategies to overcome the surgical challenge.颅颈交界区脊索瘤：病例系列及应对手术挑战的策略
J Craniovertebr Junction Spine. 2021 Oct-Dec;12(4):420-431. doi: 10.4103/jcvjs.jcvjs_87_21. Epub 2021 Dec 11.
9
Letter to the Editor Regarding "COVID-19: A Time Like No Other in (the Department of) Neurological Surgery". Should We Broaden Surgical Indications to Preserve the Standard of Care in Spinal Metastases?致编辑的信：关于“COVID-19：神经外科（部门）前所未有的时期”。我们是否应扩大手术适应症以维持脊柱转移瘤的治疗标准？
World Neurosurg. 2021 Jul;151:303-304. doi: 10.1016/j.wneu.2021.03.154.
10
Solitary late spinal metastasis from apocrine salivary duct carcinoma: Case report.乳腺大汗腺导管癌的孤立性晚期脊柱转移：病例报告
Surg Neurol Int. 2021 Mar 30;12:122. doi: 10.25259/SNI_903_2020. eCollection 2021.
本文引用的文献
1
Immunotherapy in myeloma: how far have we come?骨髓瘤的免疫疗法：我们已经取得了多大进展？
Ther Adv Hematol. 2019 Jan 18;10:2040620718822660. doi: 10.1177/2040620718822660. eCollection 2019.
2
Advances in the Treatment of Metastatic Renal Cell Carcinoma.转移性肾细胞癌的治疗进展
Cancer Treat Res. 2018;175:127-137. doi: 10.1007/978-3-319-93339-9_6.
3
New Insights in Prostate Cancer Development and Tumor Therapy: Modulation of Nuclear Receptors and the Specific Role of Liver X Receptors.前列腺癌发生发展和肿瘤治疗的新见解：核受体的调节和肝 X 受体的特定作用。
Int J Mol Sci. 2018 Aug 28;19(9):2545. doi: 10.3390/ijms19092545.
4
Recent advances in prostate cancer research: large-scale genomic analyses reveal novel driver mutations and DNA repair defects.前列腺癌研究的最新进展：大规模基因组分析揭示了新的驱动突变和DNA修复缺陷。
F1000Res. 2018 Aug 2;7. doi: 10.12688/f1000research.14499.1. eCollection 2018.
5
Metastatic Melanoma: Recent Therapeutic Progress and Future Perspectives.转移性黑色素瘤：最新治疗进展与未来展望。
Drugs. 2018 Aug;78(12):1197-1209. doi: 10.1007/s40265-018-0945-z.
6
Emerging therapies in advanced hepatocellular carcinoma.晚期肝细胞癌的新兴疗法
Exp Hematol Oncol. 2018 Aug 3;7:17. doi: 10.1186/s40164-018-0109-6. eCollection 2018.
7
Targeted therapy for metastatic colorectal cancer.转移性结直肠癌的靶向治疗。
Expert Rev Anticancer Ther. 2018 Oct;18(10):991-1006. doi: 10.1080/14737140.2018.1502664. Epub 2018 Aug 3.
8
Chimeric Antigen Receptor Therapy.嵌合抗原受体疗法
N Engl J Med. 2018 Jul 5;379(1):64-73. doi: 10.1056/NEJMra1706169.
9
Recent Advances in the Treatment of Breast Cancer.乳腺癌治疗的最新进展
Front Oncol. 2018 Jun 14;8:227. doi: 10.3389/fonc.2018.00227. eCollection 2018.
10
Chimeric antigen receptor-engineered T-cell therapy for liver cancer.嵌合抗原受体修饰的 T 细胞治疗肝癌。
Hepatobiliary Pancreat Dis Int. 2018 Aug;17(4):301-309. doi: 10.1016/j.hbpd.2018.05.005. Epub 2018 May 24.
Zotero 插件